Erlonat 100 mg can be used along with another treatment called gemcitabine if you have cancer of the pancreas at a metastatic stage. It contains the active ingredient Erlotinib, which effectively treats cancer by stopping the action of a protein called EGFR, also known as an epidermal growth factor. EGFR is a protein responsible for the growth and spread of cancer cells. Each tablet contains 100 mg of Erlotinib and needs to be taken at least an hour before or two hours after consuming food. Discuss with your doctor if you have renal impairment as you may require dose adjustment. The safety and efficacy of this anticancer agent have not been established in patients under the age of 18 years. In clinical trials, smoking has been shown to reduce Erlotinib exposure by 50-60%. Speak to your doctor for the maximum dose limit. 

The usual dose is one tablet of Erlonat 100 mg each day if you have metastatic pancreatic cancer. Take the tablet on an empty stomach. It is given in combination with gemcitabine treatment. Always take your anticancer drug exactly as your doctor has told you. You must speak to your doctor if you have any doubts about the usage of the medicine. Let your doctor know if you accidentally take too many tablets. You may have side effects, and your doctor may ask you to discontinue treatment for some time immediately. It is important to keep taking it daily as long as your doctor has prescribed it to you. If you have further questions regarding the usage of this anticancer drug, talk to your doctor.

Do not use Erlonat 100 mg if you have hypersensitivity to Erlotinib or any of the medicine ingredients. The anticancer drug should be used under the supervision of a doctor. EGFR mutation-positive status must be confirmed before starting first-line Erlonat monotherapy. The cancer drug has not been studied in patients with severe liver and kidney disorders. This anticancer therapy may result in severe or fatal adverse reactions, including Hepatotoxicity and gastrointestinal issues. The safety and effectiveness of this anticancer drug have not been studied in paediatrics. There is no evidence to suggest if elderly patients require dose adjustments. There are adequate or well-controlled studies in pregnant women using Erlotinib tablets. Women receiving this anticancer treatment must be advised to avoid pregnancy. Adequate contraceptive methods should be used during the treatment and for at least two weeks after completing therapy. It is still unknown whether the medication is excreted in human milk.  Do not breastfeed if you are being treated with this anticancer drug and for at least two weeks after taking the last tablet.

The most common side effects of pancreatic cancer are rash, diarrhoea, vomiting, pyrexia, dyspnea, stomatitis, bone pain, oedema, fatigue, nausea, and myalgia. Speak to your doctor immediately if any of these symptoms worsen. It is not recommended for use in patients with liver or kidney disorders.